CR20180043A - Antagonistas del receptor cgrp. - Google Patents

Antagonistas del receptor cgrp.

Info

Publication number
CR20180043A
CR20180043A CR20180043A CR20180043A CR20180043A CR 20180043 A CR20180043 A CR 20180043A CR 20180043 A CR20180043 A CR 20180043A CR 20180043 A CR20180043 A CR 20180043A CR 20180043 A CR20180043 A CR 20180043A
Authority
CR
Costa Rica
Prior art keywords
cgrp
receiver antagonists
antagonists
cgrp receiver
compound
Prior art date
Application number
CR20180043A
Other languages
English (en)
Inventor
Steven Marc Massey
Jason Kenneth; Myers
David Andrew; Coates
Kevin Charles; Fortner
Antonio; Navarro
Russell Dean; Stucky
Miles Goodman; Siegel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20180043A publication Critical patent/CR20180043A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona un compuesto de fórmula II: o una sal farmacéuticamente aceptable del mismo.
CR20180043A 2015-08-12 2016-08-05 Antagonistas del receptor cgrp. CR20180043A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562203996P 2015-08-12 2015-08-12
US201562266867P 2015-12-14 2015-12-14
PCT/US2016/045698 WO2017027345A1 (en) 2015-08-12 2016-08-05 Cgrp receptor antagonists

Publications (1)

Publication Number Publication Date
CR20180043A true CR20180043A (es) 2018-02-22

Family

ID=56684300

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180043A CR20180043A (es) 2015-08-12 2016-08-05 Antagonistas del receptor cgrp.

Country Status (36)

Country Link
US (1) US9708297B2 (es)
EP (1) EP3334721B1 (es)
JP (1) JP6619503B2 (es)
KR (1) KR20180030582A (es)
CN (1) CN107922385B (es)
AU (1) AU2016304769B2 (es)
BR (1) BR112018000513A2 (es)
CA (1) CA2992622A1 (es)
CL (1) CL2018000290A1 (es)
CO (1) CO2018001383A2 (es)
CR (1) CR20180043A (es)
CY (1) CY1124413T1 (es)
DK (1) DK3334721T3 (es)
DO (1) DOP2018000042A (es)
EA (1) EA201890156A1 (es)
EC (1) ECSP18009366A (es)
ES (1) ES2875600T3 (es)
HK (1) HK1249095A1 (es)
HR (1) HRP20211013T1 (es)
HU (1) HUE055609T2 (es)
IL (1) IL256572A (es)
LT (1) LT3334721T (es)
MD (1) MD3334721T2 (es)
MX (1) MX2018001672A (es)
NZ (1) NZ738990A (es)
PE (1) PE20180655A1 (es)
PH (1) PH12018500282A1 (es)
PL (1) PL3334721T3 (es)
PT (1) PT3334721T (es)
RS (1) RS62041B1 (es)
SI (1) SI3334721T1 (es)
SV (1) SV2018005631A (es)
TN (1) TN2018000026A1 (es)
TW (1) TWI636041B (es)
WO (1) WO2017027345A1 (es)
ZA (1) ZA201800452B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR111665A1 (es) * 2017-05-15 2019-08-07 Lilly Co Eli Derivados de 3-metil-pirrolidina-2,5-diona útiles como antagonistas del receptor cgrp
CN110678457B (zh) * 2017-05-15 2022-08-16 伊莱利利公司 Cgrp受体拮抗剂
WO2019112024A1 (ja) * 2017-12-08 2019-06-13 キッセイ薬品工業株式会社 ピロリジン化合物
WO2020153414A1 (ja) 2019-01-24 2020-07-30 武田薬品工業株式会社 複素環化合物及びその用途
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
US20230096051A1 (en) * 2019-12-12 2023-03-30 Eli Lilly And Company Cgrp antigonists useful as tracer compounds for positron emission tomography

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4376997A (en) * 1996-10-04 1998-05-05 Novo Nordisk A/S N-substituted azaheterocyclic compounds
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
PE20080370A1 (es) * 2006-06-08 2008-06-13 Boehringer Ingelheim Int Derivados de quinazolinona como antagonistas de cgrp
US8148390B2 (en) * 2007-03-12 2012-04-03 Merck, Sharp & Dohme, Corp. Monocyclic anilide spirolactam CGRP receptor antagonists
EP2685826B1 (en) * 2011-03-18 2016-02-03 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
EP2846798B1 (en) * 2012-05-09 2018-04-04 Merck Sharp & Dohme Corp. Aliphatic spirolactam cgrp receptor antagonists
FR3009961A1 (fr) * 2013-08-30 2015-03-06 Ct Hospitalier Universitaire De Clermont Fd Agent bloqueur des canaux cav3 dans le traitement de la douleur
WO2015161011A1 (en) * 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Benzamide cgrp receptor antagonists

Also Published As

Publication number Publication date
MD3334721T2 (ro) 2021-09-30
MX2018001672A (es) 2018-05-28
HRP20211013T1 (hr) 2021-10-01
JP2018522933A (ja) 2018-08-16
EP3334721A1 (en) 2018-06-20
PL3334721T3 (pl) 2021-10-18
PT3334721T (pt) 2021-06-17
SI3334721T1 (sl) 2021-08-31
ES2875600T3 (es) 2021-11-10
HUE055609T2 (hu) 2021-12-28
IL256572A (en) 2018-02-28
DOP2018000042A (es) 2018-10-31
EP3334721B1 (en) 2021-04-28
CO2018001383A2 (es) 2018-05-21
AU2016304769A1 (en) 2018-01-25
WO2017027345A1 (en) 2017-02-16
LT3334721T (lt) 2021-07-26
US9708297B2 (en) 2017-07-18
PE20180655A1 (es) 2018-04-17
DK3334721T3 (da) 2021-06-28
NZ738990A (en) 2019-03-29
CL2018000290A1 (es) 2018-07-13
CY1124413T1 (el) 2022-07-22
RS62041B1 (sr) 2021-07-30
AU2016304769B2 (en) 2018-09-13
PH12018500282A1 (en) 2018-08-13
ECSP18009366A (es) 2018-04-30
HK1249095A1 (zh) 2018-10-26
ZA201800452B (en) 2019-07-31
TWI636041B (zh) 2018-09-21
CN107922385A (zh) 2018-04-17
TN2018000026A1 (en) 2019-07-08
EA201890156A1 (ru) 2018-07-31
CN107922385B (zh) 2020-09-08
TW201718481A (zh) 2017-06-01
US20170044138A1 (en) 2017-02-16
KR20180030582A (ko) 2018-03-23
SV2018005631A (es) 2018-04-24
CA2992622A1 (en) 2017-02-16
BR112018000513A2 (pt) 2018-09-18
JP6619503B2 (ja) 2019-12-11

Similar Documents

Publication Publication Date Title
ECSP18009366A (es) Antagonistas del receptor de cgrp
PH12017501523A1 (en) Selective bace1 inhibitors
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
AR101995A1 (es) COMPUESTOS ANTAGONISTAS DE INTEGRINA avb6
MA39749A (fr) Dérivés de pipéridine-dione
AR095039A1 (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
MA39956A (fr) Analogues du benzomorphane et leur utilisation
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
PH12018500903A1 (en) Pyranodipyridine compound
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
SV2019005838A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
MX2018003903A (es) Compuesto biciclico y uso del mismo para inhibicion de suv39h2.
AR111665A1 (es) Derivados de 3-metil-pirrolidina-2,5-diona útiles como antagonistas del receptor cgrp
CY1119540T1 (el) Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt
EA201791596A1 (ru) Пиразоловые соединения
AR115865A2 (es) Compuestos terapéuticos
MA42602B1 (fr) Antagonistes du recepteur cgrp
AR112111A1 (es) Tetrahidropiridopirazinas moduladoras de receptores gpr6
GB201812604D0 (en) Antagonist compounds